Check out your Company Bowl for anonymous work chats.
Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced its continued influence in pharmaceutical research. With more than 200 papers authored by Certara scientists* this past year and 11 Certara scientists included on the 2025 update of Stanford/Elsevier’s ranking of the top 2% most cited scientists across the globe, Certara’s powerhouse of scientific knowledge continues to drive innovation in drug discovery and development. #Biopharma #DrugDevelopment #Certara #ScientificExcellence #Innovation
Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that the Company was certified as a Great Place to Work for the third consecutive year. The company also earned a spot on Fortune’s 2024 Best Workplaces in New York. The prestigious Great Place to Work certification draws on current employees’ experience working at Certara, as analyzed by global people analytics firm Great Place to Work®. This year, 86% of Certara employees said it’s a great place to work – 29 points higher than the average U.S. company.
The Certara team will host Career Conversations Monday, November 6 through Wednesday, November 8. Time spots are limited, so sign up today to secure your spot with our team! https://ow.ly/GORu50POiw3 Check out additional details for the event here: https://ow.ly/GORu50POiw3 #ACoP14 #Pharmacometrics #QuantitativeSystemsPharmacology #PBPKModeling #QSPModeling #Certaralovesmodels #Certaralovesmodeling #Certaralovesmodelers
PRINCETON, NJ – September 19th, 2023 – Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced it has successfully supported 300 completed submissions to regulatory agencies worldwide. Submissions include those to initiate clinical trials, such as Investigational New Drug (IND) or Clinical Trial Application (CTA) and marketing applications, such as New Drug Applications (NDA), Marketing Authorization Applications (MAA), Supplemental New Drug Applications (sNDA), Biologics License Applications (BLA), EU Type II variations, and New Drug Submissions (NDS). Certara has supported clients’ global regulatory submissions across a wide range of therapeutic areas including cancer, rare diseases, central nervous system (CNS) diseases, and pediatrics. “As the global regulatory drug development environment changes at an ever-increasing pace, Certara has combined regulatory writing expertise with technology platforms that streamline a complex process,” said Demetrius Carter, Sr. Vice President, Regulatory Sciences & Medical Affairs at Certara. “The impact for our clients has been the completion of high-quality submissions on time, resulting in faster approvals of life changing therapeutics for patients.”, said Patrick Smith, President, Certara Drug Development Solutions. Certara’s team of drug development and submission specialists have supported global submissions to the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), Medicines and He
Team Certara - Let's Beat COVID Together!
